WAWillan Patricio Robles Abarca

Willan Patricio Robles Abarca

*This is an algorithmically generated author record based on publicly available information.

Willan Patricio Robles Abarca has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of multiple myeloma in patients on hemodialysis programs

    by David Garrido, Omar Seminario, Juan Santacruz, Evelyn Moreira, Rosalina Lituma, Jorge Moscoso, Ubelis Rosales, Alfonso Silva Contreras, Victor Hugo Ortega, Angel Quevedo, et al.

    Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.


  • Open Access

    Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD: a prospective observational study

    by Franklin Geovany Mora-Bravo, Pamela Tatiana Morales Torres, Nelson Rojas Campoverde, Guillermina Lucía Blum Carcelen, Juan Cristobal Santacruz Mancheno, Ángel Cristóbal Santacruz Tipanta, Hector Perez-Grovas, Willan Patricio Robles Abarca

    Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique. Methods: The present observational, prospective study was carried out at the Pafram hemodiafiltration unit in Morona Santiago, Ecuador, and the hemodialysis unit of the Fundación Renal del Ecuador in Guayaquil, Ecuador, from August 2019 to December 2023. Patients who were receiving hemodiafiltration were included. Weight was optimized with POC-DW for eight weeks. In Group 1, patients whose use of antihypertensive drugs was not required to control systolic blood pressure with a value less than 150 mmHg predialysis, less than 130 mmHg postdialysis, and a peridialytic blood pressure (defined as post-HD minus pre-HD SBP) between 0 and − 20 mmHg were analyzed. In Group 2, patients who required antihypertensive drugs for not meeting the aims of systolic blood pressure were included. The variables included clinical, demographic, mortality, description of the treatment, and routine laboratory tests in dialysis programs. The sample was nonprobabilistic. Survival analysis was performed for the study groups. The log-rank test (Mantel-Cox) was used for survival comparisons. Results: The study included 106 patients. Optimal blood pressure control without antihypertensive treatment was achieved in 52 patients (49.1%) (Group 1). In 54 patients (50.9%), antihypertensive agents were required (Group 2). There was more significant mortality in the group that received antihypertensives: 11 patients in group 1 (21.2%) versus 25 patients in group 2 (46.3%) (P = 0.005). Survival was more significant in group 1, with an HR of 2.2163 (1.125–4.158) (P = 0.0243). Conclusion: In hemodiafiltration and hemodialysis programs, blood pressure control with active ultrafiltration measures and without using antihypertensives is essential for survival in patients with CKD.